PL3071595T3 - Humanizowane przeciwciało przeciw kalikreinie-2 - Google Patents

Humanizowane przeciwciało przeciw kalikreinie-2

Info

Publication number
PL3071595T3
PL3071595T3 PL14814696T PL14814696T PL3071595T3 PL 3071595 T3 PL3071595 T3 PL 3071595T3 PL 14814696 T PL14814696 T PL 14814696T PL 14814696 T PL14814696 T PL 14814696T PL 3071595 T3 PL3071595 T3 PL 3071595T3
Authority
PL
Poland
Prior art keywords
kalikrein
humanized antibody
antibody against
humanized
antibody
Prior art date
Application number
PL14814696T
Other languages
English (en)
Inventor
Pär Oskar Vilhelmsson TIMMERMAND
Amanda Thuy TRAN
Sven-Erik Strand
Urpo Juhani LAMMINMÄKI
Kjell SJÖSTRÖM
Original Assignee
Fredax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1320408.6A external-priority patent/GB2520353A/en
Priority claimed from GB201401973A external-priority patent/GB201401973D0/en
Application filed by Fredax Ab filed Critical Fredax Ab
Publication of PL3071595T3 publication Critical patent/PL3071595T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
PL14814696T 2013-11-19 2014-11-19 Humanizowane przeciwciało przeciw kalikreinie-2 PL3071595T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1320408.6A GB2520353A (en) 2013-11-19 2013-11-19 Antibody polypeptides and uses thereof
GB201401973A GB201401973D0 (en) 2014-02-05 2014-02-05 Antibody polypeptides and uses thereof
PCT/GB2014/053420 WO2015075445A1 (en) 2013-11-19 2014-11-19 Humanised anti kallikrein-2 antibody
EP14814696.2A EP3071595B1 (en) 2013-11-19 2014-11-19 Humanised anti kallikrein-2 antibody

Publications (1)

Publication Number Publication Date
PL3071595T3 true PL3071595T3 (pl) 2019-09-30

Family

ID=52114029

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14814696T PL3071595T3 (pl) 2013-11-19 2014-11-19 Humanizowane przeciwciało przeciw kalikreinie-2

Country Status (23)

Country Link
US (3) US10100125B2 (pl)
EP (2) EP3071595B1 (pl)
JP (4) JP6599859B2 (pl)
KR (3) KR102894975B1 (pl)
CN (2) CN112898431B (pl)
AU (3) AU2014351611B2 (pl)
BR (1) BR112016011025B1 (pl)
CA (1) CA2930493A1 (pl)
CY (1) CY1121900T1 (pl)
DK (1) DK3071595T3 (pl)
ES (1) ES2728515T3 (pl)
HR (1) HRP20191095T1 (pl)
HU (1) HUE043875T2 (pl)
IL (5) IL311788B1 (pl)
LT (1) LT3071595T (pl)
MX (2) MX383543B (pl)
PL (1) PL3071595T3 (pl)
PT (1) PT3071595T (pl)
RS (1) RS58831B1 (pl)
RU (1) RU2687163C1 (pl)
SI (1) SI3071595T1 (pl)
SM (1) SMT201900338T1 (pl)
WO (1) WO2015075445A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6101274B2 (ja) 2011-10-28 2017-03-22 フレダックス・アクチエボラーグ 治療剤およびその使用
FI3312749T3 (fi) 2012-03-05 2024-05-31 Oy Arctic Partners Ab Menetelmiä ja laitteita eturauhassyövän riskin ja eturauhasen tilavuuden ennustamiseen
US10100125B2 (en) * 2013-11-19 2018-10-16 Diaprost Ab Humanised anti kallikrein-2 antibody
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
US20180326102A1 (en) * 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
FI3548515T3 (fi) 2016-12-01 2026-03-04 Regeneron Pharma Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen
AU2018219909B2 (en) 2017-02-10 2025-02-27 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
WO2018178352A1 (en) * 2017-03-30 2018-10-04 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting prostate cancer
IL316355A (en) 2017-07-24 2024-12-01 Regeneron Pharma Anti-CD8 antibodies and their uses
EA202193076A1 (ru) 2019-05-10 2022-02-16 Янссен Байотек, Инк. Макроциклические хелаторы и способы их применения
CN114375302B (zh) * 2019-07-26 2024-12-24 詹森生物科技公司 包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途
CN114174346B (zh) * 2019-07-26 2025-08-01 詹森生物科技公司 抗hk2嵌合抗原受体(car)
IL298444A (en) 2020-05-27 2023-01-01 Janssen Biotech Inc Proteins containing cd3 antigen binding sites and uses thereof
EP4182353A1 (en) * 2020-07-17 2023-05-24 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-klk2 antibodies
WO2022101771A1 (en) 2020-11-10 2022-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of use thereof
CN112608365B (zh) * 2020-12-22 2021-07-30 吉林省特医食品生物科技有限公司 一种减轻体重的发酵型小分子肽及其制备方法和应用
WO2022156798A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
KR20230142482A (ko) 2021-01-27 2023-10-11 얀센 바이오테크 인코포레이티드 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도
EP4284839A4 (en) * 2021-01-28 2025-04-23 Astria Therapeutics, Inc. Plasma kallikrein antibodies and uses thereof
WO2022249089A1 (en) * 2021-05-27 2022-12-01 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
WO2023084397A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof
CA3240194A1 (en) 2021-11-09 2023-05-19 Edward Cleator Macrocyclic compounds and methods of making the same
US20250099635A1 (en) 2022-01-26 2025-03-27 Janssen Biotech, Inc. Iimmunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2025244971A1 (en) 2024-05-20 2025-11-27 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JP2001503991A (ja) 1996-11-14 2001-03-27 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 転移性前立腺癌の検出方法
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
CA2380912A1 (en) 1999-08-16 2001-02-22 Christopher Allen Seid Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
ATE535258T1 (de) 2001-06-01 2011-12-15 Cornell Res Foundation Inc Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
AU2002362447A1 (en) * 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
EP2347767A3 (en) 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
EP1610818A4 (en) * 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006089231A2 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
BRPI0717902A2 (pt) 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
CA2673366C (en) * 2006-12-22 2017-12-19 Phadia Ab Novel prostate kallikrein allergen
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
JP6101274B2 (ja) * 2011-10-28 2017-03-22 フレダックス・アクチエボラーグ 治療剤およびその使用
US10100125B2 (en) * 2013-11-19 2018-10-16 Diaprost Ab Humanised anti kallikrein-2 antibody
WO2023278463A1 (en) 2021-06-29 2023-01-05 Volastra Therapeutics, Inc. Anti-enpp1 antibodies and uses thereof

Also Published As

Publication number Publication date
HRP20191095T1 (hr) 2019-09-20
JP2016540503A (ja) 2016-12-28
SI3071595T1 (sl) 2019-08-30
IL311788A (en) 2024-05-01
IL297678B2 (en) 2024-09-01
CA2930493A1 (en) 2015-05-28
IL297678A (en) 2022-12-01
EP3553088A1 (en) 2019-10-16
ES2728515T3 (es) 2019-10-25
IL245617B (en) 2021-02-28
IL245617A0 (en) 2016-06-30
AU2014351611A1 (en) 2016-06-30
RS58831B1 (sr) 2019-07-31
KR102442738B1 (ko) 2022-09-15
SMT201900338T1 (it) 2019-07-11
EP3071595A1 (en) 2016-09-28
US20220064333A1 (en) 2022-03-03
BR112016011025B1 (pt) 2024-01-23
RU2016124229A (ru) 2017-12-25
IL311788B1 (en) 2025-11-01
IL278493B2 (en) 2023-04-01
KR20160096621A (ko) 2016-08-16
CY1121900T1 (el) 2020-10-14
US11230609B2 (en) 2022-01-25
AU2020207775B2 (en) 2023-06-15
CN105980404B (zh) 2021-01-12
MX2021007006A (es) 2021-09-08
IL278493A (en) 2022-12-01
HUE043875T2 (hu) 2019-09-30
US10100125B2 (en) 2018-10-16
BR112016011025A8 (pt) 2018-01-30
JP7051777B2 (ja) 2022-04-11
KR102894975B1 (ko) 2025-12-04
AU2014351611B2 (en) 2020-04-23
JP6599859B2 (ja) 2019-10-30
US20160369009A1 (en) 2016-12-22
US20190169312A1 (en) 2019-06-06
EP3553088B1 (en) 2026-03-04
CN105980404A (zh) 2016-09-28
KR20230132599A (ko) 2023-09-15
IL323633A (en) 2025-11-01
AU2023222879A1 (en) 2023-09-14
MX383543B (es) 2025-03-14
IL297678B1 (en) 2024-05-01
BR112016011025A2 (pt) 2017-12-05
LT3071595T (lt) 2019-05-10
AU2020207775A1 (en) 2020-08-06
JP2025019101A (ja) 2025-02-06
CN112898431A (zh) 2021-06-04
EP3071595B1 (en) 2019-03-20
CN112898431B (zh) 2024-05-28
PT3071595T (pt) 2019-06-11
MX2016006561A (es) 2016-12-12
KR102574537B1 (ko) 2023-09-06
JP2022062048A (ja) 2022-04-19
JP2020022470A (ja) 2020-02-13
US12404343B2 (en) 2025-09-02
WO2015075445A1 (en) 2015-05-28
KR20220020406A (ko) 2022-02-18
JP7592654B2 (ja) 2024-12-02
DK3071595T3 (da) 2019-07-01
RU2687163C1 (ru) 2019-05-07

Similar Documents

Publication Publication Date Title
CY2023021I2 (el) Αντισωματα που δεσμευουν την il-23
PL3071595T3 (pl) Humanizowane przeciwciało przeciw kalikreinie-2
DK3336106T3 (da) Anti-fcrh5-antistoffer
IL246287B (en) Fabs-in-tandem immunoglobulin and uses thereof
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
ME03675B (me) Humanizovana ili himerna anтi-cd3 antiтela
LT3049441T (lt) Anti-pdl1 antikūnų kompozicija
PT3088419T (pt) Conjugado de anticorpo anti-trop2-fármaco
DK3083694T3 (da) Caniniserede, murine anti-canin-pd-1-antistoffer
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
BR112014024769A2 (pt) anticorpo humanizado tau
KR20180085002A (ko) 인간화된 항-cll-1 항체
HRP20181478T1 (hr) Humanizirani anti-cd134 (ox40) protutijela i njihove uporabe
IL243311A0 (en) Novel antibody frameworks
EP3070168C0 (en) ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
DK3068800T3 (da) FcRn-specifikke antistoffer
DK3038643T3 (da) Antistoffer mod csf-1r
IL240753B (en) Methods for purifying antibodies
ME03094B (me) Protutijela protiv kemokina pan-elr+ схс
GB201300706D0 (en) Antibody
DK3065774T3 (da) Anti-CCL17-antistoffer
DK3047163T3 (da) Lukkeelement
HRP20190085T1 (hr) Anti-cd52 protutijela
PL3066124T4 (pl) Neuregulina-allosteryczne przeciwciała przeciwko ludzkiemu her3
PL2970503T3 (pl) Przeciwciała monoklonalne przeciw-(+) --metamfetaminie